The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis
Open accessAbstract
Uric acid (UA) is the end product of purine metabolism and can reportedly act as an antioxidant. However, recently, numerous clinical and basic research approaches have revealed close associations of hyperuricemia with several disorders, particularly those comprising the metabolic syndrome. In this review, we first outline the two molecular mechanisms underlying inflammation occurrence in relation to UA metabolism; one is inflammasome activation by UA crystallization and the other involves superoxide free radicals generated by xanthine oxidase (XO). Importantly, recent studies have demonstrated the therapeutic or preventive effects of XO inhibitors against atherosclerosis and nonalcoholic steatohepatitis, which were not previously considered to be related, at least not directly, to hyperuricemia. Such beneficial effects of XO inhibitors have been reported for other organs including the kidneys and the heart. Thus, a major portion of this review focuses on the relationships between UA metabolism and the development of atherosclerosis, nonalcoholic steatohepatitis, and related disorders. Although further studies are necessary, XO inhibitors are a potentially novel strategy for reducing the risk of many forms of organ failure characteristic of the metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 2×
“Akifumi Kushiyama,1 Yusuke Nakatsu,2 Yasuka Matsunaga,2 Takeshi Yamamotoya,2 Keiichi Mori,2 Koji Ueda,2 Yuki Inoue,2 Hideyuki Sakoda,3 Midori Fujishiro,4 Hiraku Ono,5 and Tomoichiro Asano2 1Division of Diabetes and Metabolism, Institute for Adult Disease, Asahi Life Foundation, 1-6-1 Marunouchi, Chiyoda-ku, Tokyo, Jap…”
BackgroundGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839 · cited 1×
“Since oxidative stress inactivates NO and leads to endothelial dysfunction [115], endothelial XO, especially given its enhanced expression during the development of atherosclerosis, contributes to vascular damage via ROS production.”
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Macrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Hypercholesterolemia increases endothelial superoxide anion production.
Ohara, Y., Peterson, T. E., & Harrison, D. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116491 · Cited by 1,765 · cited 1×
“Circulating XO can adhere to endothelial cells by associating with endothelial glycosaminoglycans [44].”
BackgroundActivation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
Autophagy Links Inflammasomes to Atherosclerotic Progression
Razani, B., Feng, C., Coleman, T., Emanuel, R., Wen, H., Hwang, S., Ting, J. P., Virgin, H. W., Kastan, M. B., & Semenkovich, C. F. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.02.011 · Cited by 601
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V. F. J., Ryffel, B., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1274oc · Cited by 410
White, C. R., Darley-Usmar, V, Berrington, W. R., McAdams, M., Gore, J. Z., Thompson, J. A., Parks, D. A., Tarpey, M. M., & Freeman, B. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8745 · Cited by 367
Oxidative stress in vascular disease and its pharmacological prevention
Li, H., Horke, S., & Förstermann, U. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.007 · Cited by 321
Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
Nomura, J., Busso, N., Ives, A., Matsui, C., Tsujimoto, S., Shirakura, T., Tamura, M., Kobayashi, T., So, A., & Yamanaka, Y. (2014) · Scientific Reports · doi:10.1038/srep04554 · Cited by 181 · cited 1×
“to be increased in the aortic endothelial cells of ApoEmice [114], an established model of atherosclerosis.”
BackgroundEffect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis
Agarwal, V., Hans, N., & Messerli, F. H. (2013) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00701.x · Cited by 173
Cited by
Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective
Yu, W., & Cheng, J.-D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.582680 · Cited by 344
Distinct longevity mechanisms across and within species and their association with aging
Tyshkovskiy, A., Ma, S., Shindyapina, A. V., Tikhonov, S., Lee, S.-G., Bozaykut, P., Castro, J. P., Seluanov, A., Schork, N. J., Gorbunova, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.002 · Cited by 162
Toledo-Ibelles, P., Gutiérrez-Vidal, R., Calixto-Tlacomulco, S., Delgado-Coello, B., & Mas-Oliva, J. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.04.005 · Cited by 64
Metadata
- Authors
- Kushiyama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K., Inoue, Y., Sakoda, H., Fujishiro, M., Ono, H., & Asano, T.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-15
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2565257577
- Cited by
- 174
- References
- 20
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.